Cash-strapped Far Eastern Air Transport Corp (FAT, 遠東航空) yesterday disclosed plans to sell its non-operational investments, including shares in the Xiamen Air Cargo Hub and the Kaohsiung air cargo warehouse, to meet short-term liquidity needs.
"We will sell the 12 percent shares we hold in Xiamen Air Cargo Hub (廈門航空貨運站) to the other four major shareholders for a total of NT$160 million [US$5.17 million]," FAT spokesman Hanson Chang (張有朋) said.
EVA Airways Corp (長榮航空), China Airlines Ltd (CAL; 中華航空), Taiwan Air Service Co (台灣航勤), and China's Xiamen Airport are the four major shareholders of the air cargo hub.
Chang said profits from other non-operational investments such as NT$50 million from Kaohsiung Air Food Service (高雄空儲) and NT$20 million in accounts receivable from online travel agent EZfly.com (易飛網) would help the cash crunch next week.
Chang said that a total of NT$35 million had already been received yesterday to meet the costs of operation over the weekend, as well as last month's payroll.
FAT said because of severe losses after the high-speed railway started operation and continuous surges in fuel costs, the company had gained approval from the Civil Aeronautic Administration to suspend service from Taipei to Tainan and from Kaohsiung to Hualien beginning today.
MOVING ON UP: Taiwan improved in all four areas measured by the IMD, making its biggest leap, from 17th to sixth place, in economic performance Taiwan moved up three spots from last year to place eighth, its best performance since 2013, in the latest annual world competitiveness rankings, released yesterday by the International Institute for Management Development (IMD). Innovation, digitalization, welfare benefits and social cohesion are critical to economic performance, with Switzerland, Sweden, Denmark, the Netherlands and Singapore making up the top five on the list this year, the Switzerland-based institute said, after grading 64 countries and regions based on economic performance, infrastructure, and government and business efficiency. “Leading performers are characterized by varying degrees of investment in innovation, diversified economic activities and supportive public policy,” IMD
With the US opening up to travel, demand in Taiwan for US-bound flights has soared, pushing up ticket prices to most destinations in North America, tourism sources said. Fares for destinations in the US have risen dramatically since the middle of last month, and the trend is expected to continue in the coming months, as California on Tuesday lifted most social distancing and capacity limits put in place to contain the spread of COVID-19, ezTravel Co (易遊網) said in a statement yesterday. The travel agency forecast that the number of tickets sold this month is likely to be double or triple
‘MATTER OF SURVIVAL’: Vice Premier Liu He is to lead the development of ‘third-generation’ chips, a field not yet dominated by any nation or company Chinese President Xi Jinping (習近平) is renewing his years-long push to achieve technology self-sufficiency by tapping a top deputy to shepherd a key initiative aimed at helping domestic chipmakers overcome US sanctions. Chinese Vice Premier Liu He (劉鶴), Xi’s economic czar whose sprawling portfolio spans trade to finance and technology, has been tapped to spearhead the development of so-called “third-generation” chip development and capabilities, and is leading the formulation of a series of financial and policy supports for the technology, people with knowledge of the matter said. It is a nascent field that relies on newer materials and gear beyond traditional silicon,
OPPORTUNITY: The company aims to sell its product soon, as enterovirus vaccines are not available anywhere but China, where firms are only marketing their vaccines locally Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations. The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday. Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said. The company enrolled its first participant for